Abstract
Objective To present the first year-over-year data comparison of preference signaling for residency interviews in the otolaryngology application marketplace.
Study Design Cross-sectional study conducted over 2 application cycles
Setting Otolaryngology training programs in the United States.
Methods Otolaryngology residency applicants were invited to participate in preference signaling during the 2021 and 2022 application cycles. Submissions were collected using a web-based interface. The distribution of signals among programs was evaluated descriptively and in relationship to program rankings. Surveys were sent to applicants to assess general attitudes and the number of interview invitations received from signaled and non-signaled programs. Surveys were sent to programs to evaluate use of signals and the impact on Match results.
Results Programs received a range of signals from 0-66, with 50% of signals going to 24% of programs, which was similarly found in 2021. Programs of higher rank tended to receive more signals. Overall, greater than 87% of surveyed applicants received an interview offer from at least one program they signaled. In 2021 and 2022, applicants were 2.6 times more likely to get an interview from a signaled program than from a comparator non-signaled program. A greater positive impact on interview offer rate was seen for less competitive applicants. Signaling was viewed favorably by the vast majority surveyed applicants and programs.
Conclusions Preference signaling for otolaryngology residency interviews demonstrates a promising mechanism to improve applicant visibility to programs during the application cycle. This impact is consistent over 2 application cycles.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of The University of California San Francisco gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interests: No relevant conflicts for all authors
Sponsorships: None.
Funding source: None.
Submitted for presentation at AAO-HNSF 2022 Annual Meeting
Conception, design, and drafting of the work; critically revising the work for important intellectual content; approval of the final submission; agreement to be accountable for all aspects of the work.
Data Availability
All data produced in the present study are available upon reasonable request to the authors